Cargando…

TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer

Most head and neck cancer (HNC) patients are resistant to cetuximab, an antibody against the epidermal growth factor receptor. Such therapy resistance is known to be mediated, in part, by stromal cells surrounding the tumor cells; however, the mechanisms underlying such a resistance phenotype remain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yegodayev, Ksenia M., Novoplansky, Ofra, Golden, Artemiy, Prasad, Manu, Levin, Liron, Jagadeeshan, Sankar, Zorea, Jonathan, Dimitstein, Orr, Joshua, Ben-Zion, Cohen, Limor, Khrameeva, Ekaterina, Elkabets, Moshe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073231/ https://www.ncbi.nlm.nih.gov/pubmed/32028632 http://dx.doi.org/10.3390/cancers12020339

Ejemplares similares

IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer
por: Badarni, Mai, et al.
Publicado: (2021)

Worldwide Prevalence and Clinical Characteristics of RAS Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis
por: Novoplansky, Ofra, et al.
Publicado: (2022)

Tumor Tissue Explant Culture of Patient-Derived Xenograft as Potential Prioritization Tool for Targeted Therapy
por: Ghosh, Susmita, et al.
Publicado: (2019)

Developing a dual VEGF/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy
por: Tzuri, Noam, et al.
Publicado: (2023)

The Contribution of the Minimal Promoter Element to the Activity of Synthetic Promoters Mediating CAR Expression in the Tumor Microenvironment
por: Greenshpan, Yariv, et al.
Publicado: (2022)

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer
por: Prasad, Manu, et al.
Publicado: (2022)

Cell stiffness predicts cancer cell sensitivity to ultrasound as a selective superficial cancer therapy
por: Bergman, Eden, et al.
Publicado: (2021)

IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer
por: Zorea, Jonatan, et al.
Publicado: (2018)

High parathyroid hormone levels after parathyroidectomy for parathyroid adenoma are not related to the cellularity of the remaining glands
por: Sagiv, Rotem, et al.
Publicado: (2021)

Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancers
por: Sananes, Amiram, et al.
Publicado: (2023)

Probing antibody surface density and analyte antigen incubation time as dominant parameters influencing the antibody-antigen recognition events of a non-faradaic and diffusion-restricted electrochemical immunosensor
por: Zorea, Jonathan, et al.
Publicado: (2020)

c-Met as a new marker of cellular senescence
por: Boichuck, Maria, et al.
Publicado: (2019)

Synthetic promoters to induce immune-effectors into the tumor microenvironment
por: Greenshpan, Yariv, et al.
Publicado: (2021)

TRAF3 suppression encourages B cell recruitment and prolongs survival of microbiome-intact mice with ovarian cancer
por: Zorea, Jonathan, et al.
Publicado: (2023)

Cargo-Dependent Targeted Cellular Uptake Using Quaternized Starch as a Carrier
por: Blitsman, Yossi, et al.
Publicado: (2023)

Inference of long-range cell-cell force transmission from ECM remodeling fluctuations
por: Nahum, Assaf, et al.
Publicado: (2023)

José Baselga M.D., Ph.D. (1959–2021) leading cancer researcher and oncologist
por: Elkabets, Moshe, et al.
Publicado: (2021)

Unmet Needs and Perspectives in Oral Cancer Prevention
por: Bouaoud, Jebrane, et al.
Publicado: (2022)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor of PKCs
por: Jayaram, Divya Ram, et al.
Publicado: (2021)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA
por: Nair K, Lekha, et al.
Publicado: (2011)

Evaluation of triblock copolymeric micelles of δ- valerolactone and poly (ethylene glycol) as a competent vector for doxorubicin delivery against cancer
por: Nair K, Lekha, et al.
Publicado: (2011)

Cetuximab in Refractory Skin Cancer Treatment
por: Kalapurakal, Sini J, et al.
Publicado: (2012)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

High-Throughput Screening Identified Compounds Sensitizing Tumor Cells to Glucose Starvation in Culture and VEGF Inhibitors In Vivo
por: Marciano, Ran, et al.
Publicado: (2019)

Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance
por: O’Keefe, Rachel A., et al.
Publicado: (2020)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

Evolving role of cetuximab in the treatment of colorectal cancer
por: Schuch, Gunter, et al.
Publicado: (2009)

PRSS contributes to cetuximab resistance in colorectal cancer
por: Tan, Zhaoli, et al.
Publicado: (2020)

Smurf2 E3 ubiquitin ligase modulates proliferation and invasiveness of breast cancer cells in a CNKSR2 dependent manner
por: David, Diana, et al.
Publicado: (2014)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Solanum nigrum Unripe fruit fraction attenuates Adriamycin resistance by down-regulating multi-drug resistance protein (Mdr)-1 through Jak-STAT pathway
por: Jagadeeshan, Sankar, et al.
Publicado: (2017)

PTEN status in advanced colorectal cancer treated with cetuximab
por: Negri, F V, et al.
Publicado: (2010)

Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance
por: Tak, Eunyoung, et al.
Publicado: (2022)

Ubiquitin Accumulation on Disease Associated Protein Aggregates Is Correlated with Nuclear Ubiquitin Depletion, Histone De-Ubiquitination and Impaired DNA Damage Response
por: Ben Yehuda, Adi, et al.
Publicado: (2017)

Cetuximab produced from a goat mammary gland expression system is equally efficacious as innovator cetuximab in animal cancer models
por: Wang, Qian, et al.
Publicado: (2020)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis
por: Neyns, B., et al.
Publicado: (2008)

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
por: Dahan, Laetitia, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_u727jiqc0ctcobupbqvgcqa9ka